Quantum Leap Healthcare Collaborative

Agent Information Sheet

Widely hailed as the future of phase II drug development, the adaptive I-SPY 2 platform trial has set a new benchmark for
I-SPY Trial Manuscript
<- Back to All Agents


Trade Name:
Agent Chaperone(s):
Treatment Protocol:
MK-2206 is an Allosteric AKT Inhibitor. MK-2206 was administered orally at 135mg weekly (q1w) with Paclitaxel at 80 mg/m2 weekly (q1w) for 12 weeks. This regimen was followed by AC (q2w or q3w) for 4 weeks.
Date Entered I-SPY:
September 15, 2012
Date Left I-SPY:
May 14, 2014
No. Participants in Arm:
Graduating Subtypes:
HR-, HER2+ and HR-HER2+
Agent Description:

MK2206 is an orally available, allosteric small-molecule inhibitor of AKT, In pre-clinical models, MK-2206 was shown to bind to and inhibit the activity of AKT in a non-ATP competitive manner, which may result in the inhibition of the PI3K/AKT signaling pathway. MK-2206 can inhibit tumor cell proliferation and induce apoptosis (cell death) in some of those models.

Final pCR Probabilities:
Primary Manuscript:
abstractpdfdoi link